

## REFERENCES

1. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 1997;20:1183-201.
2. Castano L, Eisenbarth GS. Type-I diabetes: A chronic autoimmune disease of human, mouse, and rat. *Annu Rev Immunol* 1990;8:647-79.
3. Reaven GM. Role of insulin resistance in human disease. *Diabetes* 1988;37:1595-607.
4. Sacks DB, McDonald JM. The pathogenesis of type II diabetes mellitus: a polygenic disease. *Am J Clin Pathol* 1996;105:149-56.
5. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. *Diabetes Care* 1998;21:296-309.
6. Nathan DM. Long-term complications of diabetes mellitus. *N Engl J Med* 1993;328:1676-85.
7. Geiss L, Engelgau M, Frazier E, Tierney E. *Diabetes Surveillance, 1997*. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, 1997.
8. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. *Diabetes* 1979;28:1039-57.
9. American Diabetes Association. Tests of glycemia in diabetes. *Diabetes Care* 2001;24 (Suppl 1):S80-2.
10. American Diabetes Association. Type 2 diabetes in children and adolescents. *Diabetes Care* 2000;23:381-9.
11. CDC Diabetes Cost-effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. *JAMA* 1998;280:1757-63.
12. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329:977-86.
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998;352:837-53.
14. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. *Diabetes Care* 2000;23 (Suppl 1):S32-42.
15. Sasaki A. Assessment of the new criteria for diabetes mellitus according to 10-year relative survival rates. *Diabetologia* 1981;20:195-8.
16. Sasaki A, Uehara M, Horiuchi N, Hasegawa K, Shimizu T. A 15-year follow-up study of patients with non-insulin-dependent diabetes mellitus (NIDDM) in Osaka, Japan. Factors predictive of the prognosis of diabetic patients. *Diabetes Res Clin Pract* 1997;36:41-7.
17. Andersson DKG, Svardsudd K. Long-term glycaemic control relates to mortality in type II diabetes. *Diabetes Care* 1995;18:1534-43.
18. Gerstein HC, Pais P, Pogue J, Yusuf S. Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. *J Amer Coll Cardiol* 1999;33:612-9.
19. Howie-Davies S, Simpson RW, Turner RC. Control of maturity-onset diabetes by monitoring fasting blood glucose and body weight. *Diabetes Care* 1980;5:607-10.
20. Muir A, Howe-Davies SA, Turner RC. General practice care of non-insulin-dependent diabetes with fasting blood glucose measurements. *Am J Med* 1982;73:637-40.
21. Harris MI. Undiagnosed NIDDM: Clinical and public health issues. *Diabetes Care* 1993;16:642-52.
22. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. *Diabetes Care* 1998;21:518-24.
23. Troisi RJ, Cowie CC, Harris MI. Diurnal variation in fasting plasma glucose: implications for diagnosis of diabetes in patients examined in the afternoon. *JAMA* 2000;284:3157-9.
24. Chan AYW, Swaminathan R, Cockram CS. Effectiveness of sodium fluoride as a preservative of glucose in blood. *Clin Chem* 1989;35:315-7.

25. Ladenson JH. Nonanalytical sources of variation in clinical chemistry results. In: Sonnenwirth A, Jarett L, eds. *Clinical Laboratory Methods and Diagnosis*. St. Louis, MO: C.V. Mosby Co., 1980:149-92.
26. Sacks DB. Carbohydrates. In: Burtis C, Ashwood E, eds. *Tietz Textbook of Clinical Chemistry*. 3rd ed. Philadelphia: Saunders, 1999:750-808.
27. Ladenson JH, Tsai LM, Michael JM, Kessler G, Joist JH. Serum versus heparinized plasma for eighteen common chemistry tests: is serum the appropriate specimen? *Am J Clin Pathol* 1974;62:545-52.
28. Larsson-Cohn U. Differences between capillary and venous blood glucose during oral glucose tolerance tests. *Scand J Clin Lab Invest* 1976;36:805-8.
29. Lind T, C. V, De Groot HA, Brown G, Cheyne GA. Observations on blood glucose and insulin determinations. *BMJ* 1972;3:320.
30. Tchobroutsky G. Blood glucose levels in diabetic and non-diabetic subjects. *Diabetologia* 1991;34:67-73.
31. Blunt BA, Barrett-Connor E, Wingard DL. Evaluation of fasting plasma glucose as screening test for NIDDM in older adults. *Diabetes Care* 1991;14:989-93.
32. DECODE. Consequences of the new diagnostic criteria for diabetes in older men and women. *Diabetes Care* 1999;22:1667-71.
33. Ferrannini E, Vichi S, Beck-Nielsen H, Laakso M, Paolisso G, Smith U. Insulin action and age. European group for the study of insulin resistance (EGIR). *Diabetes* 1996;45:947-53.
34. Genter PM, Ipp E. Accuracy of plasma glucose measurements in the hypoglycemic range. *Diabetes Care* 1994;17:595-8.
35. Fraser CG, Petersen PH. Analytical performance characteristics should be judged against objective quality specifications. *Clin Chem* 1999;45:321-3.
36. Stockl D, Baadenhuijsen H, Fraser CG, Libeer JC, Petersen PH, Ricos C. Desirable routine analytical goals for quantities assayed in serum. *Eur J Clin Chem Clin Biochem* 1995;33:157-69.
37. Fraser CG. The necessity of achieving good laboratory performance. *Diabetic Med* 1990;7:490-3.
38. Olefsky JM, Reaven GM. Insulin and glucose responses to identical oral glucose tolerance tests performed 48 hours apart. *Diabetes* 1974;23:449-53.
39. Widjaja A, Morris RJ, Levy JC, Frayn KN, Manley SE, Turner RC. Within- and between-subject variation in commonly measured anthropometric and biochemical variables. *Clin Chem* 1999;45:561-6.
40. Sebastian-Gambaro MA, Liron-Hernandez FJ, Fuentes-Arderiu X. Intra- and inter-individual biological variability data bank. *Eur J Clin Chem Clin Biochem* 1997;35:845-52.
41. Mooy JM, Grootenhuys PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter LM, et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. *Diabetologia* 1996;39:298-305.
42. Ollerton RL, Playle R, Ahmed K, Dunstan FD, Luzio SD, Owens DR. Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. *Diabetes Care* 1999;22:394-8.
43. Ricos C, Alvarez V, Cava F, Garcia-Lario JV, Hernandez A, Jimenez CV, et al. Current databases on biological variation: pros, cons and progress. *Scand J Clin Lab Invest* 1999;59:491-500.
44. Howanitz PJ, Cembrowski GS, Steindel SJ, Long TA. Physician goals and laboratory test turnaround times. A College of American Pathologists Q-Probes study of 2763 clinicians and 722 institutions. *Arch Pathol Lab Med* 1993;117:22-8.
45. Lewandrowski K, Cheek R, Nathan DM, Godine JE, Hurxthal K, Eschenbach K, et al. Implementation of capillary blood glucose monitoring in a teaching hospital and determination of program requirements to maintain quality testing. *Am J Med* 1992;4:419-26.
46. Harris MI, Cowie CC, Howie LJ. Self-monitoring of blood glucose by adults with diabetes in the United States population. *Diabetes Care* 1993;16:1116-23.
47. Thayer AM. Deciphering diseases. *Chemical and Engineering News* 1999;August 30:19-28.
48. American Diabetes Association. Self-monitoring of blood glucose. *Diabetes Care* 1996;19 (Suppl 1):S62-6.
49. Faas A, Schellevis FG, van Eijk JTM. The efficacy of self-monitoring of blood glucose in NIDDM subjects. *Diabetes Care* 1997;20:1482-6.

50. Coster S, Gulliford MC, Seed PT, Powrie JK, Swaminathan R. Self-monitoring in Type 2 diabetes mellitus: a meta-analysis. *Diabet Med* 2000;17:755-61.
51. Harris MI. Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes. *Diabetes Care* 2001;24:979-82.
52. Gerich JE, Mokan M, Veneman T, Korytkowski M, Mitrakou A. Hypoglycemia unawareness. *Endocrine Rev* 1991;12:356-71.
53. Tang Z, Lee JH, Louie RF, Kost GJ. Effects of different hematocrit levels on glucose measurements with handheld meters for point-of-care testing. *Arch Pathol Lab Med* 2000;124:1135-40.
54. American Diabetes Association. Consensus statement on self-monitoring of blood glucose. *Diabetes Care* 1994;17:81-6.
55. Tate PF, Clements CA, Walters JE. Accuracy of home blood glucose monitors. *Diabetes Care* 1992;15:536-8.
56. Chan JC, Wong RY, Cheung CK, Lam P, Chow CC, Yeung VT, et al. Accuracy, precision and user-acceptability of self blood glucose monitoring machines. *Diabetes Res Clin Pract* 1997;36:91-104.
57. Kabadi UM, O'Connell KM, Johnson J, Kabadi M. The effect of recurrent practice at home on the acceptability of capillary blood glucose readings. Accuracy of self blood glucose testing. *Diabetes Care* 1994;10:1110-23.
58. American Diabetes Association Buyer's Guide. *Diabetes Forecast*. 2001;54:46-110.
59. Burnett RW, D'Orazio P, Fogh-Andersen N, Kuwa K, Kulpmann WR, Larsson L, et al. IFCC recommendation on reporting results for blood glucose. *Clin Chim Acta* 2001;307:205-9.
60. Weitgasser R, Gappmayer B, Pichler M. Newer portable glucose meters - analytical improvement compared with previous generation devices? *Clin Chem* 1999;45:1821-5.
61. American Diabetes Association. Consensus statement on self-monitoring of blood glucose. *Diabetes Care* 1987;10:93-9.
62. Barr JT, Betschart J, Bracey A. Ancillary (bedside) blood glucose testing in acute and chronic care facilities. *NCCLS* 1994;14:1-14.
63. Clarke WL, Cox D, Goder-Frederick LA, Carter W, Pohl SL. Evaluating clinical accuracy of systems for self-monitoring of blood glucose. *Diabetes Care* 1987;10:622-8.
64. Skeie S, Thue G, Sandberg S. Patient-derived quality specifications for instruments used in self-monitoring of blood glucose. *Clin Chem* 2001;47:67-73.
65. Boyd JC, Bruns DE. Quality specifications for glucose meters: assessment by simulation modeling of errors in insulin dose. *Clin Chem* 2001;47:209-14.
66. Novis DA, Jones BA. Interinstitutional comparison of bedside blood glucose monitoring program characteristics, accuracy performance, and quality control documentation. *Arch Pathol Lab Med* 1998;122:495-502.
67. Brunner GA, Ellmerer M, Sendlhofer G, Wutte A, Trajanoski Z, Schaupp L, et al. Validation of home blood glucose meters with respect to clinical and analytical approaches. *Diabetes Care* 1998;21:585-90.
68. Schiffrin A, Belmonte M. Multiple daily self-glucose monitoring: its essential role in long-term glucose control in insulin-dependent diabetic patients treated with pump and multiple subcutaneous injections. *Diabetes Care* 1982;5:479-84.
69. Nathan DS. The importance of intensive supervision in determining the efficacy of insulin pump therapy. *Diabetes Care* 1983;6:295-7.
70. De Veciana M, Major CA, Morgan MA, Tamerou A, Toohey JS, Lien J, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. *N Engl J Med* 1995;333:1237-41.
71. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998;15:539-53.
72. The Expert Committee. The expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 1999;22:S5-19.
73. Gimeno SGA, Ferreira SRG, Franco LJ, Junes M. The Japanese-Brazilian Diabetes Study Group. Comparison of glucose tolerance categories according to World Health Organization and American Diabetes Association diagnostic criteria in a population-based study in Brazil. *Diabetes Care* 1998;21:1889-992.
74. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study [see comments]. *Diabetes Care* 1999;22:920-4.

75. Perry RC, Baron AD. Impaired glucose tolerance. Why is it not a disease? *Diabetes Care* 1999;22:883-5.
76. Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. *World Health Organization. Diabetes Res Clin Pract* 1999;44:21-6.
77. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Comparison of diabetes diagnostic categories in the U.S. population according to the 1997 American Diabetes Association and 1980-1985 World Health Organization diagnostic criteria [see comments]. *Diabetes Care* 1997;20:1859-62.
78. Balkau B. The DECODE study. *Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Diabetes Metab* 2000;26:282-6.
79. Ko GT, Chan JC, Woo J, Lau E, Yeung VT, Chow CC, et al. The reproducibility and usefulness of the oral glucose tolerance test in screening for diabetes and other cardiovascular risk factors. *Ann Clin Biochem* 1998;35:62-7.
80. Moses RG, Patterson MJ, Regan JM, Chanchaiyakul R, Taylor NA, Jenkins AB. A non-linear effect of ambient temperature on apparent glucose tolerance. *Diabetes Res Clin Pract* 1997;36:35-40.
81. Ganda OP, Day JL, Soeldner JS, Connon JJ, Gleason RE. Reproducibility and comparative analysis of repeated intravenous and oral glucose tolerance tests. *Diabetes* 1978;27:715-25.
82. American Diabetes Association. Gestational diabetes mellitus. *Diabetes Care* 2000;23:S77-9.
83. Barzilay JI, Spiekerman CF, Wahl PW, Kuller LH, Cushman M, Furberg CD, et al. Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria [see comments]. *Lancet* 1999;354:622-5.
84. Naylor CD, Sermer M, Chen E, Sykora K. Cesarean delivery in relation to birth weight and gestational glucose tolerance: pathophysiology or practice style? Toronto Trihospital Gestational Diabetes Investigators. *JAMA* 1996;275:1165-70.
85. DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. *Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe* [see comments]. *Lancet* 1999;354:617-21.
86. Hoffman L, Nolan C, Wilson JD, Oats JJ, Simmons D. Gestational diabetes mellitus—management guidelines. The Australasian Diabetes in Pregnancy Society. *Med J Aust* 1998;169:93-7.
87. Colman PG, Thomas DW, Zimmet PZ, Welborn TA, Garcia-Webb P, Moore MP. New classification and criteria for diagnosis of diabetes mellitus. Position Statement from the Australian Diabetes Society, New Zealand Society for the Study of Diabetes, Royal College of Pathologists of Australasia and Australasian Association of Clinical Biochemists. *Med J Aust* 1999;170:375-8.
88. Metzger BE, Coustan DR. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee. *Diabetes Care* 1998;21:B161-7.
89. American Diabetes Association. Tests of glycemia in diabetes. *Diabetes Care* 1999;22:S77-9.
90. Goldstein DE, Little RR, Lorenz RA, Malone JJ, Nathan D, Peterson CM. Tests of glycemia in diabetes. *Diabetes Care* 1995;18:896-909.
91. Pickup J, Rolinski O, Birch D. In vivo glucose sensing for diabetes management: progress towards non-invasive monitoring [interview by Judy Jones]. *BMJ* 1999;319:1289-92.
92. Khalil OS. Spectroscopic and clinical aspects of noninvasive glucose measurements. *Clin Chem* 1999;45:165-77.
93. Smith KM. Oak Ridge Conference. Introduction. *Clin Chem* 1999;45:1586.
94. Bloomgarden ZT. American Diabetes Association Annual Meeting, 1999. New approaches to insulin treatment and glucose monitoring. *Diabetes Care* 1999;22:2078-82.
95. Haupt K, Mosbach K. Plastic antibodies: developments and applications. *Trends Biotechnol* 1998;16:468-75.
96. Chen G, Guan Z, Chen CT, Fu L, Sundaresan V, Arnold FH. A glucose-sensing polymer. *Nature Biotechnol* 1997;15:354-7.
97. James TC, Sananayake DRAS, Shinkai S. A glucose-selective molecular fluorescence sensor. *Angewandte Chemie International Edition in English* 1994;33:2207-9.
98. Birch DJS, Imhof RE. Time-domain fluorescence spectroscopy using time-correlated single-photon counting. *Topics in Fluorescence Spectroscopy* 1994;1:1-95.

99. Tolosa L, Szmacinski H, Rao G, Lakowicz JR. Lifetime-based sensing of glucose using energy transfer with a long lifetime donor. *Anal Biochem* 1997;250:102-8.
100. Rolinski OJ, Birch DJS, McCartney LJ, Pickup JC. Near-infrared assay for glucose determination. *Soc Photo-optical Instrumentation Engineers Proc* 1999;3602:6-14.
101. Marvin JS, Hellinga HW. Engineering biosensors by introducing fluorescent allosteric signal transducers: construction of a novel glucose sensor. *J Am Chem Soc* 1998;120:7-11.
102. Hoss U, Gessler R, Kalatz B, Salgado MI, Sternberg F, Fussganger R. Calibration-free continuous on-line glucose monitoring: the comparative microdialysis technique. *Diabetologia* 1998;41 (suppl 1):45A.
103. Bolinder J, Ungerstedt U, Arner P. Microdialysis measurement of the absolute glucose concentration in subcutaneous adipose tissue allowing glucose monitoring in diabetic patients. *Diabetologia* 1992;35:1177-80.
104. Meyerhoff C, Bischof F, Sternberg F, Zier H, Pfeiffer EF. On line continuous monitoring of subcutaneous tissue glucose in men by combining portable glucosensor with microdialysis. *Diabetologia* 1992;35:1087-92.
105. Hashiguchi Y, Sakakida M, Nishida K, Uemura T, Kajiwara K, Shichiri M. Development of a miniaturized glucose monitoring system by combining a needle-type glucose sensor with microdialysis sampling method. Long-term subcutaneous tissue glucose monitoring in ambulatory diabetic patients. *Diabetes Care* 1994;17:387-96.
106. Tamada JA, Garg S, Jovanovic L, Pitzer KR, Fermi S, Potts RO. Noninvasive glucose monitoring: comprehensive clinical results. Cygnus Research Team. *JAMA* 1999;282:1839-44.
107. Garg SK, Potts RO, Ackerman NR, Fermi SJ, Tamada JA, Chase HP. Correlation of fingerstick blood glucose measurements with GlucoWatch biographer glucose results in young subjects with type 1 diabetes. *Diabetes Care* 1999;22:1708-14.
108. Arnold MA. Non-invasive glucose monitoring. *Curr Opin Biotechnol* 1996;7:46-9.
109. Robinson MR, Eaton RP, Haaland DM, Koepf GW, Thomas EV, Stallard BR, et al. Noninvasive glucose monitoring in diabetic patients: a preliminary evaluation. *Clin Chem* 1992;38:1618-22.
110. Marbach R, Koschinski T, Gries FA, Heise HM. Non-invasive blood glucose assay by near-infrared diffuse reflectance spectroscopy of the human lip. *Appl Spectroscopy* 1993;47:875-81.
111. Kajiwara K, Uemura T, Kishikawa H, Nishida K, Hashiguchi Y, Uehara M, et al. Noninvasive measurement of blood glucose concentrations by analysing Fourier transform infra-red absorbance spectra through oral mucosa. *Med Biol Eng Comput* 1993;31:S17-22.
112. Gabriely I, Wozniak R, Mevorach M, Kaplan J, Aharon Y, Shamon H. Transcutaneous glucose measurement using near-infrared spectroscopy during hypoglycemia. *Diabetes Care* 1999;22:2026-32.
113. Heinemann L, Schmelzeisen-Redeker G. Non-invasive continuous glucose monitoring in Type I diabetic patients with optical glucose sensors. Non-Invasive Task Force (NITF). *Diabetologia* 1998;41:848-54.
114. Maier JS, Walker SA, Fantini S, Francheschini MA, Gratton E. Possible correlation between blood glucose concentration and the reduced light scattering coefficient of tissues in the near infrared. *Optics Lett* 1994;19:2062-4.
115. Christison GB, MacKenzie HA. Laser photoacoustic determination of physiological glucose concentrations in human whole blood. *Med Biol Eng Comput* 1993;31:284-90.
116. MacKenzie HA, Ashton HS, Spiers S, Shen Y, Freeborn SS, Hannigan J. Blood glucose measurements by photoacoustics. *Biomed Optical Spectroscopy Diagnostics* 1998;22:156-9.
117. MacKenzie HA, Ashton HS, Spiers S, Shen Y, Freeborn SS, Hannigan J, et al. Advances in photoacoustic noninvasive glucose testing. *Clin Chem* 1999;45:1587-95.
118. Kreisberg RA. Diabetic ketoacidosis: new concepts and trends in pathogenesis and treatment. *Ann Intern Med* 1978;88:681-95.
119. Owen OE, Trapp VE, Skutches CL, Mozzoli MA, Hoeldtke RD, Boden G, et al. Acetone metabolism during diabetic ketoacidosis. *Diabetes* 1982;31:242-8.
120. Stephens JM, Sulway MJ, Watkins PJ. Relationship of blood acetoacetate and 3-hydroxybutyrate in diabetes. *Diabetes* 1971;20:485-9.
121. Porter WH, Yao HH, Karounos DG. Laboratory and clinical evaluation of assays for beta-hydroxybutyrate. *Am J Clin Pathol* 1997;107:353-8.
122. American Diabetes Association. Tests of glycemia (Position Statement). *Diabetes Care* 2000;23 (Suppl 1):S80-2.

123. Csako G. Causes, consequences, and recognition of false-positive reactions for ketones. *Clin Chem* 1990;36:1388-9.
124. Rosenbloom AL, Malone JI. Recognition of impending ketoacidosis delayed by ketone reagent strip failure. *JAMA* 1978;240:2462-4.
125. McMurray CH, Blanchflower WJ, Rice DA. Automated kinetic method for D-3-hydroxybutyrate in plasma or serum. *Clin Chem* 1984;30:421-5.
126. Koch DD, Feldbruegge DH. Optimized kinetic method for automated determination of beta-hydroxybutyrate. *Clin Chem* 1987;33:1761-6.
127. D'arrigo T. Beyond blood glucose. *Diabetes Forecast* 1999;52:37-8.
128. Westphal SA. The occurrence of diabetic ketoacidosis in non-insulin-dependent diabetes and newly diagnosed diabetic adults. *Am J Med* 1996;101:19-24.
129. Jovanovic-Petersen L, Peterson CM. Sweet success, but an acid aftertaste? *N Engl J Med* 1991;325:959-60.
130. Mercer DW, Losos FJ, 3rd, Mason L, Kessler GF, Jr. Monitoring therapy with insulin in ketoacidotic patients by quantifying 3-hydroxybutyrate with a commercial kit. *Clin Chem* 1986;32:224-5.
131. Wiggam MI, O'Kane MJ, Harper R, Atkinson AB, Hadden DR, Trimble ER, et al. Treatment of diabetic ketoacidosis using normalization of blood 3-hydroxybutyrate concentration as the endpoint of emergency management. A randomized controlled study. *Diabetes Care* 1997;20:1347-52.
132. Umpierrez GE, Watts NB, Phillips LS. Clinical utility of beta-hydroxybutyrate determined by reflectance meter in the management of diabetic ketoacidosis. *Diabetes Care* 1995;18:137-8.
133. American Diabetes Association. Implications of the Diabetes Control and Complications Trial (position statement). *Diabetes Care* 2000;23 (Suppl 1):S24-6.
134. Davidson MB. Diabetes research and diabetes care. Where do we stand? *Diabetes Care* 1998;21:2152-60.
135. American Diabetes Association. Provider Notes: the newsletter of the ADA/NCQA Provider Recognition Program. 2000;1:1-4.
136. Bunn HF. Nonenzymatic glycosylation of protein: relevance to diabetes. *Am J Med* 1981;70:325-30.
137. Jovanovic L, Peterson CM. The clinical utility of glycosylated hemoglobin. *Am J Med* 1981;70:331-38.
138. Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. *N Engl J Med* 1984;310:341-6.
139. Goldstein DE, Little RR, Wiedmeyer HM, England JD, McKenzie EM. Glycated hemoglobin: methodologies and clinical applications. *Clin Chem* 1986;32:B64-70.
140. Goldstein DE, Little RR, England JD, Wiedemeyer H-M, McKenzie E. Methods of glycosylated hemoglobins: high performance liquid chromatography and thiobarbituric acid colorimetric methods. In: Clarke WL, Larner J, Pohl SL, eds. *Methods in diabetes research*, Vol 2. New York: John Wiley, 1986:475-504.
141. Tahara Y, Shima K. The response of GHb to stepwise plasma glucose change over time in diabetic patients. *Diabetes Care* 1993;16:1313-4.
142. Svendsen PA, Lauritzen T, Soegaard U, Nerup J. Glycosylated haemoglobin and steady-state mean blood glucose concentration in Type 1 (insulin-dependent) diabetes. *Diabetologia* 1982;23:403-5.
143. Cefalu WT, Wang ZQ, Bell-Farrow A, Kiger FD, Izlar C. Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia. *Clin Chem* 1994;40:1317-21.
144. Singer DE, Coley CM, Samet JH, Nathan DM. Tests of glycemia in diabetes mellitus. Their use in establishing a diagnosis and in treatment. *Ann Int Med* 1989;110:125-37.
145. Molnar GD. Clinical evaluation of metabolic control in diabetes. *Diabetes* 1978;27:216-25.
146. UK Prospective Diabetes Study. Reduction in HbA1c with basal insulin supplement, sulfonylurea or biguanide therapy in maturity-onset diabetes. *Diabetes* 1985;34:793-8.
147. Baker JR, Johnson RN, Scott DJ. Serum fructosamine concentrations in patients with type II (non-insulin-dependent) diabetes mellitus during changes in management. *B M J (Clin Res Ed)* 1984;288:1484-6.

148. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. *Diabetes Care* 1995;18:440-7.
149. Little RR, Goldstein DE. Measurements of glycated haemoglobin and other circulating glycated proteins. In: Mogensen CE, Standl E, eds. *Research methodologies in human diabetes-Part I*. Berlin: W. de Gruyter, 1994:299-317.
150. Peterson CM, Jovanovic L, Raskin P, Goldstein DE. A comparative evaluation of glycosylated haemoglobin assays: feasibility of references and standards. *Diabetologia* 1984;26:214-7.
151. Little RR, Wiedmeyer HM, England JD, Wilke AL, Rohlfing CL, Wians FH, Jr., et al. Interlaboratory standardization of measurements of glycohemoglobins. *Clin Chem* 1992;38:2472-8.
152. Bodor GS, Little RR, Garrett N, Brown W, Goldstein DE, Nahm MH. Standardization of glycohemoglobin determinations in the clinical laboratory: three years of experience. *Clin Chem* 1992;38:2414-8.
153. Weykamp CW, Penders TJ, Muskiet FA, van der Slik W. Effect of calibration on dispersion of glycohemoglobin values determined by 111 laboratories using 21 methods. *Clin Chem* 1994;40:138-44.
154. Little RR, Goldstein DE. Standardization of glycohemoglobin measurements. *AACC Endo* 1995;13:109-24.
155. Goldstein DE, Little RR. Bringing order to chaos: the National Glycohemoglobin Standardization Program. *Contemp Int Med* 1997;9:27-32.
156. NGSP steering committee. Implementation of the national glycohemoglobin standardization program (NGSP). *Diabetes* 1997;46:151A.
157. Little RR, Rohlfing CL, Wiedmeyer H-M, Myers GL, Sacks DB, Goldstein DE. The National Glycohemoglobin Standardization Program (NGSP): A five-year progress report. *Clin Chem* 2001;47:1985-92.
158. DCCT Research Group. Feasibility of centralized measurements of glycated hemoglobin in the diabetes control and complications trial: a multicenter study. *Clin Chem* 1987;33:2267-71.
159. Wiener K, Roberts NB. Age does not influence levels of HbA1c in normal subject. *Q J Med* 1999;92:169-73.
160. Kilpatrick ES, Dominiczak MH, Small M. The effects of ageing on glycation and the interpretation of glycaemic control in Type 2 diabetes. *Q J Med* 1996;89:307-12.
161. Nuttall FQ. Effect of age on the percentage of hemoglobin A1c and the percentage of total glycohemoglobin in non-diabetic persons. *J Lab Clin Med* 1999;134:451-3.
162. Davie SJ, Gould BJ, Yudkin JS. Effects of vitamin C on glycosylation of proteins. *Diabetes Care* 2000;23:339-44.
163. Ceriello A, Giugliano D, Quattraro A, Donzella C, Dipalo G, Lefebvre PJ. Vitamin E reduction of protein glycosylation in diabetes. New prospect for prevention of diabetic complications? *Diabetes Care* 1991;14:68-72.
164. Tarim O, Kucukerdogan A, Gunay U, Eralp O, Ercan I. Effects of iron deficiency anemia on hemoglobin A1c in type 1 diabetes mellitus. *Pediatr Int* 1999;41:357-62.
165. Nathan DM, Francis TB, Palmer JL. Effect of aspirin on determinations of glycosylated hemoglobin. *Clin Chem* 1983;29:466-9.
166. Stevens VJ, Fantl WJ, Newman CB, Sims RV, Cerami A, Peterson CM. Acetaldehyde adducts with hemoglobin. *J Clin Invest* 1981;67:361-9.
167. Ceriello A, Giugliano D, Dello Russo P, Sgambato S, D'Onofrio F. Increased glycosylated haemoglobin A1 in opiate addicts: evidence for a hyperglycaemic effect of morphine. *Diabetologia* 1982;22:379.
168. Roberts WL, Chiasera JM, Ward-Cook KM. Glycohemoglobin results in samples with hemoglobin C or S trait: a comparison of four test systems. *Clin Chem* 1999;45:906-9.
169. Weykamp CW, Penders TJ, Muskiet FA, van der Slik W. Influence of hemoglobin variants and derivatives on glycohemoglobin determinations, as investigated by 102 laboratories using 16 methods. *Clin Chem* 1993;39:1717-23.
170. Schnedl WJ, Krause R, Halwachs-Baumann G, Trinker M, Lipp RW, Krejs GJ. Evaluation of HbA1c determination methods in patients with hemoglobinopathies. *Diabetes Care* 2000;23:339-44.
171. Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. *Clin Chem* 2001;47:153-63.
172. Rendell M, Brannan C, Nierenberg J, Rasbold K, Hestorff T. Fingertstick glycosylated hemoglobin, plasma protein, and albumin. *Diabetes Care* 1987;10:629-32.

173. Ferrell RE, Hanis CL, Aguilar L, Tulloch B, Garcia C, Schull WJ. Glycosylated hemoglobin determination from capillary blood samples. Utility in an epidemiologic survey of diabetes. *Am J Epidemiol* 1984;119:159-66.
174. Little RR, England JD, Wiedmeyer HM, Goldstein DE. Effects of whole blood storage on results for glycosylated hemoglobin as measured by ion-exchange chromatography, affinity chromatography, and colorimetry. *Clin Chem* 1983;29:1113-5.
175. Little RR, England JD, Wiedmeyer HM, Goldstein DE. Glycosylated hemoglobin measured by affinity chromatography: micro-sample collection and room-temperature storage. *Clin Chem* 1983;29:1080-2.
176. Baglin SK, Brown AS. Two capillary blood-collection techniques for estimating glycohemoglobin compared. *Clin Chem* 1995;41:330-2.
177. Voss EM, Cembrowski GS, Clasen BL, Spencer ML, Ainslie MB, Haig B. Evaluation of capillary collection system for HbA1c specimens. *Diabetes Care* 1992;15:700-1.
178. Little RR, Wiedmeyer HM, D. H. A simple blood collection device for analysis of glycohemoglobin (GHB). *Clin Chem* 1998;44:A139.
179. Baynes JW, Bunn HF, Goldstein D, Harris M, Martin DB, Peterson C, et al. National Diabetes Data Group: report of the expert committee on glucosylated hemoglobin. *Diabetes Care* 1984;7:602-6.
180. Marshall SM, Barth JH. Standardization of HbA1c measurements: a consensus statement. *Ann Clin Biochem* 2000;37:45-6.
181. Goldstein DE, Peth SB, England JD, Hess RL, Da Costa J. Effects of acute changes in blood glucose on HbA1c. *Diabetes* 1980;29:623-8.
182. Bannon P. Effect of pH on the elimination of the labile fraction of glycosylated hemoglobin. *Clin Chem* 1982;28:2183.
183. Cagliero E, Levina EV, Nathan DM. Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. *Diabetes Care* 1999;22:1785-9.
184. DCCT Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. *Diabetes* 1995;44:968-83.
185. Larsen ML, Horder M, Mogensen EF. Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes mellitus. *N Engl J Med* 1990;323:1021-5.
186. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 2000;23:S4-18.
187. Peters AL, Davidson MB, Schriger DL, Hasselblad V. A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. *JAMA* 1996;276:1246-52.
188. Harris MI, Eastman RC. Early detection of undiagnosed non-insulin-dependent diabetes mellitus. *JAMA* 1996;276:1261-2.
189. Rohlfing CL, Little RR, Wiedmeyer HM, England JD, Madsen R, Harris MI, et al. Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. *Diabetes Care* 2000;23:187-91.
190. McCance DR, Hanson RL, Charles MA, Jacobsson LT, Pettitt DJ, Bennett PH, et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. *BMJ* 1994;308:1323-8.
191. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, et al. Advanced glycosylation end products in patients with diabetic nephropathy. *N Engl J Med* 1991;325:836-42.
192. Hoelzel W, Miedema K. Development of a reference system for the international standardization of HbA1c/glycohemoglobin determinations. *J Int Fed Clin Chem* 1996;9:62-4, 66-7.
193. Kobold U, Jeppsson JO, Dulffer T, Finke A, Hoelzel W, Miedema K. Candidate reference methods for hemoglobin A1c based on peptide mapping. *Clin Chem* 1997;43:1944-51.
194. Eckfeldt JH, Bruns DE. Another step towards standardization of methods for measurement of hemoglobin A1c [Editorial]. *Clin Chem* 1997;43:1811-3.
195. Miedema K. Electrospray mass spectrometry for measurement of glycohemoglobin. *Clin Chem* 1997;43:705-7.
196. Todd JA. Genetics of type 1 diabetes. *Pathol Biol (Paris)* 1997;45:219-27.
197. She JX. Susceptibility to type I diabetes: HLA-DQ and DR revisited [see comments]. *Immunol Today* 1996;17:323-9.



198. Ziegler AG, Bachmann W, Rabl W. Prophylactic insulin treatment in relatives at high risk for type 1 diabetes. *Diabetes Metab Rev* 1993;9:289-93.
199. Rewers M, Bugawan TL, Norris JM, Blair A, Beaty B, Hoffman M, et al. Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY). *Diabetologia* 1996;39:807-12.
200. Kukreja A, Maclaren NK. Autoimmunity and diabetes. *J Clin Endocrinol Metab* 1999;84:4371-8.
201. Klein J, Sato A. The HLA system. First of two parts. *N Engl J Med* 2000;343:702-9.
202. Taylor SI, Arioglu E. Genetically defined forms of diabetes in children. *J Clin Endocrinol Metab* 1999;84:4390-6.
203. Fajans SS, Bell GI, Bowden DW, Halter JB, Polonsky KS. Maturity onset diabetes of the young (MODY). *Diabet Med* 1996;13:S90-5.
204. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. *Lancet* 2001;358:221-9.
205. Harrison LC. Risk assessment, prediction and prevention of type 1 diabetes. *Pediatric Diabetes* 2001;2:71-82.
206. Redondo MJ, Kawasaki E, Mulgrew CL, Noble JA, Erlich HA, Freed BM, et al. DR- and DQ-associated protection from type 1A diabetes: comparison of DRB1\*1401 and DQA1\*0102-DQB1\*0602\*. *J Clin Endocrinol Metab* 2000;85:3793-7.
207. Maclaren NK, Kukreja A. Type 1 diabetes. In: Sly WS, ed. *The metabolic and molecular bases of inherited disease*. 8th ed. St. Louis: McGraw-Hill, 2001:1471-88.
208. Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK, et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. *Science* 1983;222:1337-9.
209. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase [published erratum appears in *Nature* 1990 Oct 25;347(6295):782]. *Nature* 1990;347:151-6.
210. Kaufman DL, Erlander MG, Clare-Salzler M, Atkinson MA, Maclaren NK, Tobin AJ. Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. *J Clin Invest* 1992;89:283-92.
211. Atkinson MA, Maclaren NK. Islet cell autoantigens in insulin-dependent diabetes. *J Clin Invest* 1993;92:1608-16.
212. Lan MS, Wasserfall C, Maclaren NK, Notkins AL. IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. *Proc Natl Acad Sci U S A* 1996;93:6367-70.
213. Lu J, Li Q, Xie H, Chen ZJ, Borovitskaya AE, Maclaren NK, et al. Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. *Proc Natl Acad Sci U S A* 1996;93:2307-11.
214. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group [published erratum appears in *Lancet* 1998 Jan 31;351(9099):376]. *Lancet* 1997;350:1288-93.
215. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (Latent Autoimmune Diabetes of the Adult): Definition, characterization, and potential prevention. *Diabetes Care* 2001;24:1460-7.
216. Maclaren N, Lan M, Coutant R, Schatz D, Silverstein J, Muir A, et al. Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2beta predict immune-mediated (Type 1) diabetes in relatives. *J Autoimmun* 1999;12:279-87.
217. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, et al. Prediction of type 1 diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. *Diabetes* 1996;45:926-33.
218. Schott M, Schatz D, Atkinson M, Krischer J, Mehta H, Vold B, et al. GAD65 autoantibodies increase the predictability but not the sensitivity of islet cell and insulin autoantibodies for developing insulin dependent diabetes mellitus. *J Autoimmun* 1994;7:865-72.
219. Braghi S, Bonifacio E, Secchi A, Di Carlo V, Pozza G, Bosi E. Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes. *Diabetes* 2000;49:218-24.
220. Zimmet P, Turner R, McCarty D, Rowley M, Mackay I. Crucial points at diagnosis. Type 2 diabetes or slow type 1 diabetes. *Diabetes Care* 1999;22:B59-64.
221. Petersen JS, Dyrberg T, Damm P, Kuhl C, Molsted-Pedersen L, Buschard K. GAD65 autoantibodies in women with gestational or insulin dependent diabetes mellitus diagnosed during pregnancy. *Diabetologia* 1996;39:1329-33.

222. Fuchtenbusch M, Ferber K, Standl E, Ziegler AG. Prediction of type 1 diabetes postpartum in patients with gestational diabetes mellitus by combined islet cell autoantibody screening: a prospective multicenter study. *Diabetes* 1997;46:1459-67.
223. Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. *Diabetes* 1996;45:622-6.
224. Gleichmann H, Bottazzo GF. Progress toward standardization of cytoplasmic islet cell-antibody assay. *Diabetes* 1987;36:578-84.
225. Mire-Sluis AR, Gaines Das R, Lernmark A. The World Health Organization International Collaborative Study for islet cell antibodies. *Diabetologia* 2000;43:1282-92.
226. Williams AJ, Bingley PJ, Bonifacio E, Palmer JP, Gale EA. A novel micro-assay for insulin autoantibodies. *J Autoimmun* 1997;10:473-8.
227. Verge CF, Stenger D, Bonifacio E, Colman PG, Pilcher C, Bingley PJ, et al. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. *Diabetes* 1998;47:1857-66.
228. Ellis TM, Schatz DA, Ottendorfer EW, Lan MS, Wasserfall C, Salisbury PJ, et al. The relationship between humoral and cellular immunity to IA-2 in IDDM. *Diabetes* 1998;47:566-9.
229. Atkinson MA, Bowman MA, Campbell L, Darrow BL, Kaufman DL, Maclaren NK. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes [see comments]. *J Clin Invest* 1994;94:2125-9.
230. Aanstoot HJ, Kang SM, Kim J, Lindsay LA, Roll U, Knip M, et al. Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in type 1 diabetes. *J Clin Invest* 1996;97:2772-83.
231. American Diabetes Association. Diabetes nephropathy. *Diabetes Care* 1999;22 (Suppl 1):S66-9.
232. Holl RW, Grabert M, Thon A, Heinze E. Urinary excretion of albumin in adolescents with type 1 diabetes: persistent versus intermittent microalbuminuria and relationship to duration of diabetes, sex, and metabolic control. *Diabetes Care* 1999;22:1555-60.
233. Sikka R, Waters J, Moore W, Sutton DR, Herman WH, Aubert RE. Renal assessment practices and the effect of nurse case management of health maintenance organization patients with diabetes. *Diabetes Care* 1999;22:1-6.
234. Howey JE, Browning MC, Fraser CG. Biologic variation of urinary albumin: consequences for analysis, specimen collection, interpretation of results, and screening programs. *Am J Kidney Dis* 1989;13:35-7.
235. Collins AC, Sethi M, MacDonald FA, Brown D, Viberti GC. Storage temperature and differing methods of sample preparation in the measurement of urinary albumin. *Diabetologia* 1993;36:993-7.
236. MacNeil ML, Mueller PW, Caudill SP, Steinberg KK. Considerations when measuring urinary albumin: precision, substances that may interfere, and conditions for sample storage. *Clin Chem* 1991;37:2120-3.
237. Hishiki S, Tochikubo O, Miyajima E, Ishii M. Circadian variation of urinary microalbumin excretion and ambulatory blood pressure in patients with essential hypertension. *J Hypertens* 1998;16:2101-8.
238. Roberts WL, Calcote CB, Cook CB, Gordon DL, Moore ML, Moore S, et al. Comparison of four commercial urinary albumin (microalbumin) methods: implications for detecting diabetic nephropathy using random urine specimens. *Clin Chim Acta* 1998;273:21-33.
239. Poulsen PL, Hansen B, Amby T, Terkelsen T, Mogensen CE. Evaluation of a dipstick test for microalbuminuria in three different clinical settings, including the correlation with urinary albumin excretion rate. *Diabetes Metab* 1992;18:395-400.
240. Fernandez Fernandez I, Paez Pinto JM, Hermosin Bono T, Vazquez Garijo P, Ortiz Camunez MA, Tarilonte Delgado MA. Rapid screening test evaluation for microalbuminuria in diabetes mellitus. *Acta Diabetol* 1998;35:199-202.
241. Leong SO, Lui KF, Ng WY, Thai AC. The use of semi-quantitative urine test-strip (Micral Test) for microalbuminuria screening in patients with diabetes mellitus. *Singapore Med J* 1998;39:101-3.
242. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. *Am J Cardiol* 1999;83:25F-29F.
243. Reaven GM. Insulin resistance and its consequences; non-insulin dependent diabetes mellitus and coronary heart disease. In: LeRoith D, Taylor SI, Olefsky JM, eds. *Diabetes Mellitus: A Fundamental Clinical Text*. Philadelphia: Lippincott-Raven, 1996:509-19.

244. Chevenne D, Trivin F, Porquet D. Insulin assays and reference values. *Diabetes Metab* 1999;25:459-76.
245. Del Prato S. Measurement of insulin resistance in vivo. *Drugs* 1999;58:3-6; discussion 75-82.
246. Marks V. Recognition and differential diagnosis of spontaneous hypoglycaemia. *Clin Endocrinol (Oxf)* 1992;37:309-16.
247. Faber OK, Binder C. C-peptide: an index of insulin secretion. *Diabetes Metab Rev* 1986;2:331-45.
248. Robbins DC, Andersen L, Bowsher R, Chance R, Dinesen B, Frank B, et al. Report of the American Diabetes Association's Task Force on standardization of the insulin assay. *Diabetes* 1996;45:242-56.
249. Marks V. Hypoglycemia: factitious and felonious. *Endocrinol Metab Clin North Am* 1999;28:579-601.
250. Health Care Financing Administration. C-Peptide levels as a criterion for use of the insulin pump. <http://www.hcfa.gov/coverage/8b3-ss2.htm> (May 14, 2001)
251. Burge MR, Schade DS. Insulins. *Endocrinol Metab Clin North Am* 1997;26:575-98.
252. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. *Proc Natl Acad Sci U S A* 1987;84:8628-32.
253. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. *Proc Natl Acad Sci U S A* 1987;84:3881-5.
254. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. *Nature* 1994;372:425-32.
255. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. *Nature* 1998;395:763-70.
256. Clement K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. *Nature* 1998;392:398-401.
257. Wingard DL, Barrett-Connor E. Heart disease in diabetes in America. 2nd ed: National Diabetes Data Group. NIH, 1995.
258. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* 1998;339:229-34.
259. Warnick GR. Measurement of cholesterol and other lipoprotein constituents in the clinical laboratory. *Clin Chem Lab Med* 2000;38:287-300.
260. Haffner SM. Management of dyslipidemia in adults with diabetes. *Diabetes Care* 1998;21:160-78.
261. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *Jama* 2001;285:2486-97.
262. Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? *Ann Intern Med* 1999;130:933-7.
263. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. *Circulation* 2000;102:1082-5.
264. Morrow DA, Ridker PM. C-reactive protein, inflammation, and coronary risk. *Med Clin North Am* 2000;84:149-61, ix.
265. Harjai KJ. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen. *Ann Intern Med* 1999;131:376-86.
266. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. *Ann Intern Med* 2000;133:81-91.
267. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. *N Engl J Med* 1999;340:1449-54.